Utility of the XXXX classification for @entity2590 syndromes: investigation of prognostic factors in 237 cases.

@entity1 @entity7139 @entity12188 @entity2590 @entity1503 @entity1334 @entity1778 @entity2008 @entity309
The utility and prognostic significance of the @entity1334 classification was studied in 237 @entity1 with a @entity2590 . No significant differences in actuarial survival and probability of transformation to acute @entity1778 were found in @entity1 with @entity309 , AISA or @entity12188 . The median survival time for the @entity309 group was 50 months, for the AISA and @entity12188 subclasses more than 60 months. The probability of transformation for the @entity309 , AISA and @entity12188 subgroups showed a linear trend with a probability of 25% for the @entity309 , 16% for the AISA and of 18% for the @entity12188 groups after a 5 year observation period. A uniformly poor prognosis was found for the @entity7139 and @entity7139 /t subgroups with median survival times of respectively 9 and 6 months. @entity2008 were found in 68 out of 155 @entity1 (44%). @entity1 with only normal metaphases or with abnormal metaphases together with karyotypic normal cells had a longer median survival time and a lower probability for transformation as compared to those with only abnormal metaphases. The most important factor in prognosis is the number of blast cells in blood and bone marrow. Age and sex, and certain quantitative and qualitative @entity1503 appear of limited prognostic value for @entity1 with @entity309 , AISA and @entity12188 . The longer life expectancy of 35 @entity1 with @entity12188 as compared to other series seems to be related to the percentage of blast cells at the time of diagnosis.
